Vincerx Pharma Analyst Ratings
Vincerx Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 274.11% | Chardan Capital | $4 → $3 | Maintains | Buy |
| 08/12/2022 | 523.52% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 06/08/2022 | 897.63% | Cantor Fitzgerald | $22 → $8 | Maintains | Overweight |
| 06/07/2022 | 648.22% | B. Riley Securities | $12 → $6 | Maintains | Buy |
| 06/07/2022 | 398.82% | Chardan Capital | $11 → $4 | Maintains | Buy |
| 06/07/2022 | 648.22% | SVB Leerink | $19 → $6 | Maintains | Outperform |
| 05/13/2022 | 1271.74% | Chardan Capital | $14 → $11 | Maintains | Buy |
| 05/13/2022 | 2269.37% | SVB Leerink | $20 → $19 | Maintains | Outperform |
| 03/30/2022 | 2394.08% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 03/30/2022 | 3391.71% | HC Wainwright & Co. | $25 → $28 | Maintains | Buy |
| 01/14/2022 | 3017.6% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/23/2021 | 3017.6% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 11/01/2021 | 2892.89% | SVB Leerink | → $24 | Initiates Coverage On | → Outperform |
| 09/13/2021 | 3641.11% | Laidlaw & Co. | → $30 | Initiates Coverage On | → Buy |
| 08/25/2021 | 3142.3% | B. Riley Securities | → $26 | Initiates Coverage On | → Buy |
| 08/13/2021 | 3641.11% | Chardan Capital | $33 → $30 | Maintains | Buy |
| 01/06/2021 | 4015.23% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/17/2022 | 274.11% | 查爾丹資本 | $4 → $3 | 維護 | 買 |
| 08/12/2022 | 523.52% | SVB Leerink | $6 → $5 | 維護 | 跑贏大盤 |
| 06/08/2022 | 897.63% | 康託·菲茨傑拉德 | $22 → $8 | 維護 | 超重 |
| 06/07/2022 | 648.22% | B.萊利證券 | $12 → $6 | 維護 | 買 |
| 06/07/2022 | 398.82% | 查爾丹資本 | $11 → $4 | 維護 | 買 |
| 06/07/2022 | 648.22% | SVB Leerink | $19 → $6 | 維護 | 跑贏大盤 |
| 05/13/2022 | 1271.74% | 查爾丹資本 | $14 → $11 | 維護 | 買 |
| 05/13/2022 | 2269.37% | SVB Leerink | $20 → $19 | 維護 | 跑贏大盤 |
| 03/30/2022 | 2394.08% | SVB Leerink | $24 → $20 | 維護 | 跑贏大盤 |
| 03/30/2022 | 3391.71% | HC Wainwright公司 | $25 → $28 | 維護 | 買 |
| 01/14/2022 | 3017.6% | HC Wainwright公司 | → $25 | 開始承保 | →購買 |
| 12/23/2021 | 3017.6% | 康託·菲茨傑拉德 | → $25 | 開始承保 | →超重 |
| 11/01/2021 | 2892.89% | SVB Leerink | → $24 | 開始承保 | →跑贏大盤 |
| 09/13/2021 | 3641.11% | 萊德勞公司 | → $30 | 開始承保 | →購買 |
| 08/25/2021 | 3142.3% | B.萊利證券 | → $26 | 開始承保 | →購買 |
| 08/13/2021 | 3641.11% | 查爾丹資本 | $33 → $30 | 維護 | 買 |
| 01/06/2021 | 4015.23% | 查爾丹資本 | → $33 | 開始承保 | →購買 |
What is the target price for Vincerx Pharma (VINC)?
Vincerx Pharma(Vinc)的目標價是多少？
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Chardan Capital on November 17, 2022. The analyst firm set a price target for $3.00 expecting VINC to rise to within 12 months (a possible 274.11% upside). 12 analyst firms have reported ratings in the last year.
查爾丹資本於2022年11月17日報道了Vincerx Pharma(納斯達克：VUC)的最新目標價。這家分析公司將目標價定為3美元，預計VUC將在12個月內上漲(漲幅可能為274.11)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Vincerx Pharma (VINC)?
Vincerx Pharma(Vinc)的最新分析師評級是多少？
The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Chardan Capital, and Vincerx Pharma maintained their buy rating.
對Vincerx Pharma(納斯達克代碼：VUC)的最新分析師評級由查爾丹資本提供，Vincerx Pharma維持買入評級。
When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?
Vincerx Pharma(VUC)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Vincerx Pharma的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Vincerx Pharma的上一次評級是在2022年11月17日提交的，所以你應該預計下一次評級將在2023年11月17日左右的某個時候公佈。
Is the Analyst Rating Vincerx Pharma (VINC) correct?
分析師對Vincerx Pharma(Vinc)的評級正確嗎？
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $4.00 to $3.00. The current price Vincerx Pharma (VINC) is trading at is $0.80, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Vincerx Pharma(VUC)評級維持不變，目標價在4.00美元至3.00美元之間。Vincerx Pharma目前的交易價格為0.80美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。